Még nem toboroz
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07441200· 2. fázis· NS Pharma, Inc.· Forrás
Toboroz
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· 3. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
NCT07481981· 3. fázis· Insmed Incorporated· Forrás
Toboroz
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)
2025-524040-35-00· 3. fázis· Generate Biomedicines Inc.· Forrás
Toboroz
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
NCT07418931· 2. fázis· Gruppo Oncologico Italiano di Ricerca Clinica· Forrás
Toboroz
ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"
NCT07381764· 2. fázis· Gruppo Oncologico Italia Meridionale· Forrás
Toboroz
Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial - GOIRC-02-2024
2024-519798-20-00· 2. fázis· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691· Janssen Research & Development, LLC· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
2024-513613-12-00· 1/2. fázis· Novartis Pharma AG· Forrás
Toboroz
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients
2024-519322-20-00· 3. fázis· Gruppo Oncologico Dell'Italia Meridionale· Forrás
Toboroz
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
NCT07284121· Hoffmann-La Roche· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· 3. fázis· Amgen· Forrás
Toboroz
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
NCT06994377· European Institute of Oncology· Forrás
Toboroz
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916· 3. fázis· Immunovant Sciences GmbH· Forrás
Fut, nem toboroz
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
NCT06856850· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Forrás
Toboroz
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT06663098· 2. fázis· Gruppo Oncologico Italiano di Ricerca Clinica· Forrás
Toboroz
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients
NCT05291156· 2. fázis· Gruppo Oncologico Dell'Italia Meridionale· Forrás
Meghívásos bevonás
TELEMACO-S: a Telemonitoring Project in Cardiology and Technology Transfer
NCT07375251· Valentina Micheluzzi· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· 2. fázis· GlaxoSmithKline· Forrás
Toboroz
Effect of Prehabilitation on Head and Neck Cancer Patients
NCT06593639· Istituti Clinici Scientifici Maugeri SpA· Forrás
Meghívásos bevonás
Validation of a Multidimensional Scale for the Detection of Health Needs in People With HIV
NCT07077642· Giovanni Di Perri· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE-2 trial)
2023-509551-14-00· 3. fázis· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Forrás
Toboroz
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
NCT05934084· Fondazione Italiana Linfomi - ETS· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· 3. fázis· ViiV Healthcare· Forrás
Fut, nem toboroz
Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
NCT05710198· 3. fázis· Omikron Italia S.r.l.· Forrás
Toboroz
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698· Hamilton Health Sciences Corporation· Forrás
Fut, nem toboroz
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
The Italian Transthyretin Amyloidosis Web-Network
NCT05444920· Fondazione IRCCS Policlinico San Matteo di Pavia· Forrás
Fut, nem toboroz
A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial
2024-516157-41-00· 2. fázis· G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica· Forrás
Toboroz
Comparison between single and dual therapy with drugs that inhibits platelet aggregation in patient undergoing the percutaneous left atrial appenDAge closure (ARMYDA-AMULET in which people will be allocated by chance to receive two different options of treatment and which will involves different clinical sites)
2024-515361-34-00· 4. fázis· Fondazione Toscana Gabriele Monasterio· Forrás
Fut, nem toboroz
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
NCT04959448· Regeneron Pharmaceuticals· Forrás
Toboroz
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
NCT04184505· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· 3. fázis· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Fut, nem toboroz
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
NCT04378855· Gruppo Italiano Malattie EMatologiche dell'Adulto· Forrás
Toboroz
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to customize therapy.
NCT04174612· 3. fázis· Fondazione G.I.M.Em.A Franco Mandelli Ets· Forrás